In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Drug-resistant epilepsy (DRE) is a form of epilepsy that is defined as a failure of adequate trials of 2 tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom.
To bridge the gap in the Drug-Resistant Epileptic market, pharmaceutical companies including PTC Therapeutics, Aquestive Therapeutics, Marinus Pharmaceuticals, Neuroelectrics, Insightec and Brainsonix Corp are dynamically operating in the DRE market landscape. The Drug-resistant epilepsy pipeline possesses few potential drugs in late- and mid-stage developments that are expected to enter the market in the near future like Vatiquinone, Libervant, and Ganaxolone. As per the DelveInsight, “Drug-resistant epilepsy market dynamics is expected to change positively in the coming years”.
For more details, visit: Drug-Resistant Epilepsy Pipeline Therapies